Clinical Trials Arena on MSN
Roche eyes Gazyva label expansion on positive phase III kidney disease data
If Gazyva gains approval in membranous nephropathy, it would have four approved indications under its belt as the drug’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results